Research Study

A Randomized, Double-blind, Parallel Group Phase 3 Study to Assess the Clinical Efficacy and Safety of 100 mg Subcutaneous Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps
Principal Investigator 
Arif Janjua

Overview

Body Locations and Systems 
Nose Injuries and Disorders
ClinicalTrials.gov# 
NCT03085797
Status 
Closed for Recruitment
Study Start/End 
Feb 8, 2018 to Sep 1, 2020
Locations 
Diamond Health Care Centre
Name/Title 
Philzah Othman - Research Coordinator
Purpose of Study 

The purpose of this study is to assess the clinical efficacy and safety of 100 milligram subcutaneous mepolizumab as an add-on to maintenance treatment in adults with severe bilateral nasal polyps.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.